A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Name: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Published: 2021
License: Public Domain

Jazz Pharmaceuticals · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

chemotherapy immunotherapy

gastric neoplasms, gastroesophageal adenocarcinoma, esophageal adenocarcinoma, her2, bispecific antibody, biparatopic antibody, immunotherapy, gastric cancers, esophageal cancers, chemotherapy, fp, capecitabine

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 915027
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.